Borbála Körmendy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Borbála Körmendy has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Kata Illés
Department of Otorhinolaryngology, Head and Neck Surgery, Bajcsy-Zsilinkszky Hospital, Budapest, Hungary
2 shared publications - Tamás Horváth
Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
2 shared publications - Alexander Schulze Wenning
Centre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
1 shared publication Alexander Shulze Wenning
Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
1 shared publicationAndrea Harnos
Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
1 shared publicationBence Bajor
Department of Otorhinolaryngology, Head and Neck Surgery, Bajcsy-Zsininszky Hospital, Budapest, Hungary
1 shared publication
Latest Publications
- Open Access
- 1 June 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (9) , 5609-5620
Modeling residual cholesteatoma growth rate: a meta-analysis of individual participant data
Purpose: To create a model of residual cholesteatoma growth rate that can be used to estimate optimal timing of follow-up imaging. Methods: Following the recommendations of the PRISMA-IPD guideline and after registering our study protocol on PROSPERO (CRD42023465320), a systematic search was completed in September 2023 and updated in July 2024, conducted in PubMed, Web of Science, Embase, and Cochrane Library. Reference lists of the resulting articles were also searched for potential inclusions. Our search yielded 11,274 articles. Studies with patients of any age and sex diagnosed with residual cholesteatoma were included if data on cholesteatoma size at follow-up were available, collected from imaging results or through second-stage surgery. For statistical analysis, a Monte Carlo simulation approach was applied, and a baseline random-intercept mixed-effects model was fitted. Results: We included 11 articles reporting individual data from 163 patients. All but one of these articles proved to be high risk of bias. Our simulation models suggest that 95% of cholesteatomas reach or grow past the size of 3 millimetres (threshold for imaging) after 28–35 months and 95% of reach or grow past the size of 5 millimetres (threshold for intraoperative identification) after 47–58 months. Conclusion: Analyzing previously published data suggests that residual cholesteatoma may only be radiologically detectable on non-EPI DWI MRI after 28–35 months postoperatively in 95% of patients, indicating delayed follow-up for average risk patients compared to current clinical practice. However, this simulation model, based on retrospective data, aims to uncover growth patterns rather than posing as a new guideline.
- 1 June 2026
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 283 (9) , 5609-5620
Open AccessModeling residual cholesteatoma growth rate: a meta-analysis of individual participant data
Purpose: To create a model of residual cholesteatoma growth rate that can be used to estimate optimal timing of follow-up imaging. Methods: Following the recommendations of the PRISMA-IPD guideline and after registering our study protocol on PROSPERO (CRD42023465320), a systematic search was completed in September 2023 and updated in July 2024, conducted in PubMed, Web of Science, Embase, and Cochrane Library. Reference lists of the resulting articles were also searched for potential inclusions. Our search yielded 11,274 articles. Studies with patients of any age and sex diagnosed with residual cholesteatoma were included if data on cholesteatoma size at follow-up were available, collected from imaging results or through second-stage surgery. For statistical analysis, a Monte Carlo simulation approach was applied, and a baseline random-intercept mixed-effects model was fitted. Results: We included 11 articles reporting individual data from 163 patients. All but one of these articles proved to be high risk of bias. Our simulation models suggest that 95% of cholesteatomas reach or grow past the size of 3 millimetres (threshold for imaging) after 28–35 months and 95% of reach or grow past the size of 5 millimetres (threshold for intraoperative identification) after 47–58 months. Conclusion: Analyzing previously published data suggests that residual cholesteatoma may only be radiologically detectable on non-EPI DWI MRI after 28–35 months postoperatively in 95% of patients, indicating delayed follow-up for average risk patients compared to current clinical practice. However, this simulation model, based on retrospective data, aims to uncover growth patterns rather than posing as a new guideline.
- Open Access
- 18 November 2025
- Published by SAGE Publications in Ear, Nose & Throat Journal
Endoscopic Control of Hard-to-Access Sites During Microscopic Cholesteatoma Surgery
Purpose: Residual cholesteatoma poses a great challenge in middle ear surgery. Considering that microscopes only offer line-of-sight vision, it was suggested earlier that endoscopes might prove useful to control difficult-to-visualize areas during surgery to ensure total evacuation of squamous epithelium. In this retrospective chart study, we evaluated intraoperative endoscopic findings of difficult-to-access sites in the tympanic cavity and postoperative cholesteatoma recidivism rate in these areas in a patient cohort who underwent primarily microscopic surgery. Main findings: Residual cholesteatoma mass was intraoperatively detected in difficult-to-visualize areas using an endoscope during 50% of the procedures (10 cases), mostly in the sinus tympani (6 cases), but also in the supratubal recess (3 cases). During a mean follow-up of 36.1 months (range: 20-59 months, targeted magnetic resonance imaging [MRI] mean follow-up: 31.3 [range: 12-59]), recurrent attic cholesteatoma was found in 2 patients (10%), and residual disease was detected with dedicated MRI sequences in another 2 cases (10%). None of the residual cholesteatomas developed in the endoscopically controlled areas. The mean air-bone gap closure at 1 year was 1.9 ± 10.2 dB (range: −18.3-21.7). Conclusions: Intraoperative endoscopic surveillance helps uncovering hidden cholesteatoma mass during routine microscopic surgery and thus offers an effective control of residual disease in these areas during a medium-term follow-up.
- 18 November 2025
- Published by SAGE Publications in Ear, Nose & Throat Journal
Open AccessEndoscopic Control of Hard-to-Access Sites During Microscopic Cholesteatoma Surgery
Purpose: Residual cholesteatoma poses a great challenge in middle ear surgery. Considering that microscopes only offer line-of-sight vision, it was suggested earlier that endoscopes might prove useful to control difficult-to-visualize areas during surgery to ensure total evacuation of squamous epithelium. In this retrospective chart study, we evaluated intraoperative endoscopic findings of difficult-to-access sites in the tympanic cavity and postoperative cholesteatoma recidivism rate in these areas in a patient cohort who underwent primarily microscopic surgery. Main findings: Residual cholesteatoma mass was intraoperatively detected in difficult-to-visualize areas using an endoscope during 50% of the procedures (10 cases), mostly in the sinus tympani (6 cases), but also in the supratubal recess (3 cases). During a mean follow-up of 36.1 months (range: 20-59 months, targeted magnetic resonance imaging [MRI] mean follow-up: 31.3 [range: 12-59]), recurrent attic cholesteatoma was found in 2 patients (10%), and residual disease was detected with dedicated MRI sequences in another 2 cases (10%). None of the residual cholesteatomas developed in the endoscopically controlled areas. The mean air-bone gap closure at 1 year was 1.9 ± 10.2 dB (range: −18.3-21.7). Conclusions: Intraoperative endoscopic surveillance helps uncovering hidden cholesteatoma mass during routine microscopic surgery and thus offers an effective control of residual disease in these areas during a medium-term follow-up.
- Open Access
- 13 February 2024
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 281 (7) , 3557-3568
Predicting residual cholesteatoma with the Potsic staging system still lacks evidence: a systematic review and meta-analysis
Purpose: To investigate the rate of residual disease in the Potsic staging system for congenital cholesteatomas. Methods: A protocol registration was published on PROSPERO (CRD42022383932), describing residual disease as a primary outcome and hearing improvement as secondary. A systematic search was performed in four databases (PubMed, Embase, Cochrane Library, Web of Science) on December 14, 2022. Articles were included if cholesteatomas were staged according to the Potsic system and follow-up duration was documented. Risk of bias was evaluated using the Quality In Prognosis Studies (QUIPS) tool. In the statistical synthesis a random effects model was used. Between-study heterogeneity was assessed using I2. Results: Thirteen articles were found to be eligible for systematic review and seven were included in the meta-analysis section. All records were retrospective cohort studies with high risk of bias. Regarding the proportions of residual disease, analysis using the χ2 test showed no statistically significant difference between Potsic stages after a follow-up of minimum one year (stage I 0.06 (confidence interval (CI) 0.01–0.33); stage II 0.20 (CI 0.09–0.38); stage III 0.06 (CI 0.00–0.61); stage IV: 0.17 (CI 0.01–0.81)). Postoperative and preoperative hearing outcomes could not be analyzed due to varied reporting. Results on cholesteatoma location and mean age at staging were consistent with those previously published. Conclusion: No statistically significant difference was found in the proportions of residual disease between Potsic stages, thus the staging system’s applicability for outcome prediction could not be proven based on the available data. Targeted studies are needed for a higher level of evidence.
- 13 February 2024
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 281 (7) , 3557-3568
Open AccessPredicting residual cholesteatoma with the Potsic staging system still lacks evidence: a systematic review and meta-analysis
Purpose: To investigate the rate of residual disease in the Potsic staging system for congenital cholesteatomas. Methods: A protocol registration was published on PROSPERO (CRD42022383932), describing residual disease as a primary outcome and hearing improvement as secondary. A systematic search was performed in four databases (PubMed, Embase, Cochrane Library, Web of Science) on December 14, 2022. Articles were included if cholesteatomas were staged according to the Potsic system and follow-up duration was documented. Risk of bias was evaluated using the Quality In Prognosis Studies (QUIPS) tool. In the statistical synthesis a random effects model was used. Between-study heterogeneity was assessed using I2. Results: Thirteen articles were found to be eligible for systematic review and seven were included in the meta-analysis section. All records were retrospective cohort studies with high risk of bias. Regarding the proportions of residual disease, analysis using the χ2 test showed no statistically significant difference between Potsic stages after a follow-up of minimum one year (stage I 0.06 (confidence interval (CI) 0.01–0.33); stage II 0.20 (CI 0.09–0.38); stage III 0.06 (CI 0.00–0.61); stage IV: 0.17 (CI 0.01–0.81)). Postoperative and preoperative hearing outcomes could not be analyzed due to varied reporting. Results on cholesteatoma location and mean age at staging were consistent with those previously published. Conclusion: No statistically significant difference was found in the proportions of residual disease between Potsic stages, thus the staging system’s applicability for outcome prediction could not be proven based on the available data. Targeted studies are needed for a higher level of evidence.